Protalix BioTherapeutics, Inc. (PLX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income $4.67M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income $21.15M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income $2.13M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income $1.17M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | $4.67M | (m) | (m) | (m) | $593.00K* | -$10.40M* | (m) | $4.35M | $3.11M | $1.08M |
| 2026-03-31 | Reported | (m) | $21.15M | (m) | (m) | (m) | $761.00K | $22.02M | (m) | $5.43M | $3.05M | $2.82M |
| 2025-09-30 | Reported | (m) | $2.13M | (m) | (m) | (m) | $498.00K* | -$3.73M* | (m) | $4.47M | $2.93M | -$116.00K |
| 2025-06-30 | Reported | (m) | $1.17M | (m) | (m) | (m) | $431.00K* | -$5.23M* | (m) | $5.99M | $2.62M | $497.00K |
| 2025-03-31 | Reported | (m) | -$4.14M | (m) | (m) | (m) | $306.00K | -$5.06M | (m) | $3.48M | $2.60M | -$113.00K |
| 2024-09-30 | Reported | (m) | $3.99M | (m) | (m) | (m) | $87.00K* | $4.11M* | (m) | $3.00M | $2.60M | $607.00K |
| 2024-06-30 | Reported | (m) | -$2.43M | (m) | (m) | (m) | $172.00K* | -$3.61M* | (m) | $2.96M | $3.48M | -$69.00K |
| 2024-03-31 | Reported | (m) | -$4.86M | (m) | (m) | (m) | $598.00K | $4.19M | (m) | $2.89M | $3.12M | -$138.00K |
| 2023-09-30 | Reported | (m) | -$1.89M | (m) | (m) | (m) | $447.00K* | -$6.89M* | (m) | $3.67M | $3.67M | $133.00K |
| 2023-06-30 | Reported | (m) | $20.42M | (m) | (m) | (m) | $204.00K* | $4.97M* | (m) | $4.47M | $4.03M | $308.00K |
| 2023-03-31 | Reported | (m) | -$2.46M | (m) | (m) | (m) | $248.00K | -$3.00M | (m) | $5.85M | $3.12M | $195.00K |
| 2022-09-30 | Reported | (m) | -$3.13M | (m) | (m) | (m) | $58.00K* | -$9.20M* | (m) | $7.39M | $2.85M | (m) |
| 2022-06-30 | Reported | (m) | -$5.52M | (m) | (m) | (m) | $128.00K* | -$7.36M* | (m) | $7.58M | $2.61M | (m) |
| 2022-03-31 | Reported | (m) | -$1.87M | (m) | (m) | (m) | $229.00K | -$5.83M | (m) | $8.77M | $3.15M | (m) |
| 2021-09-30 | Reported | (m) | -$1.89M | (m) | (m) | (m) | $344.00K* | -$1.88M* | (m) | $7.28M | $2.95M | (m) |
| 2021-06-30 | Reported | (m) | -$9.17M | (m) | (m) | (m) | $281.00K* | $6.52M* | (m) | $7.69M | $3.17M | (m) |
| 2021-03-31 | Reported | (m) | -$3.71M | (m) | (m) | (m) | $386.00K | -$9.83M | (m) | $7.12M | $3.14M | (m) |
| 2020-09-30 | Reported | (m) | -$2.58M | (m) | (m) | (m) | $102.00K* | -$3.60M* | (m) | $7.69M | $2.82M | (m) |
| 2020-06-30 | Reported | (m) | -$2.24M | (m) | (m) | (m) | $212.00K* | -$7.83M* | (m) | $9.19M | $2.19M | (m) |
| 2020-03-31 | Reported | (m) | $4.69M | (m) | (m) | (m) | $66.00K | -$7.12M | (m) | $10.34M | $3.19M | (m) |
| 2019-12-31 | Reported | (m) | $2.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Reported | (m) | -$1.54M | (m) | (m) | (m) | $392.00K* | -$3.23M* | (m) | $10.00M | $2.59M | (m) |
| 2019-06-30 | Reported | (m) | -$5.84M | (m) | (m) | (m) | $37.00K* | -$5.17M* | (m) | $13.32M | $2.07M | (m) |
| 2019-03-31 | Reported | (m) | -$5.53M | (m) | (m) | (m) | $170.00K | -$7.28M | (m) | $11.70M | $2.23M | (m) |
| 2018-12-31 | Reported | (m) | -$3.67M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | Reported | (m) | -$3.74M | (m) | (m) | (m) | $104.00K* | $13.64M* | (m) | $10.07M | $4.09M | (m) |
| 2018-06-30 | Reported | (m) | -$6.74M | (m) | (m) | (m) | $145.00K* | -$7.96M* | (m) | $7.48M | $2.16M | (m) |
| 2018-03-31 | Reported | (m) | -$5.15M | (m) | (m) | (m) | $249.00K | -$9.41M | (m) | $7.29M | $2.50M | (m) |
| 2017-09-30 | Reported | (m) | -$7.76M | (m) | (m) | (m) | $138.00K* | -$10.54M* | (m) | $7.12M | $2.84M | (m) |
| 2017-06-30 | Reported | (m) | -$10.80M | (m) | (m) | (m) | $323.00K* | -$8.62M* | (m) | $9.30M | $2.81M | (m) |
| 2017-03-31 | Reported | (m) | -$6.37M | (m) | (m) | (m) | $220.00K | -$8.43M | (m) | $5.97M | $2.54M | (m) |
| 2016-09-30 | Reported | (m) | -$6.65M | (m) | (m) | (m) | $157.00K* | -$3.44M* | (m) | $6.35M | $2.01M | (m) |
| 2016-06-30 | Reported | (m) | -$9.93M | (m) | (m) | (m) | $324.00K* | -$11.69M* | (m) | $10.01M | $2.21M | (m) |
| 2016-03-31 | Reported | (m) | -$7.86M | (m) | (m) | (m) | $251.00K | -$9.63M | (m) | $7.33M | $2.00M | (m) |
| 2015-09-30 | Reported | (m) | -$5.00M | (m) | (m) | (m) | $128.00K* | -$8.66M* | (m) | $5.07M | $2.16M | (m) |
| 2015-06-30 | Reported | (m) | -$5.58M | (m) | (m) | (m) | $233.00K* | -$5.35M* | (m) | $6.02M | $2.00M | (m) |
| 2015-03-31 | Reported | (m) | -$5.38M | (m) | (m) | (m) | $99.00K | -$6.42M | (m) | $6.10M | $1.82M | (m) |
| 2014-09-30 | Reported | (m) | -$6.21M | (m) | (m) | (m) | $246.00K* | (m) | (m) | $8.05M | $2.01M | (m) |
| 2014-06-30 | Reported | (m) | -$5.45M | (m) | (m) | (m) | $108.00K* | (m) | (m) | $7.08M | $1.57M | (m) |
| 2014-03-31 | Reported | (m) | -$6.47M | (m) | (m) | (m) | $263.00K | (m) | (m) | $8.15M | $3.71M | (m) |
| 2013-09-30 | Reported | (m) | -$5.64M | (m) | (m) | (m) | $327.00K* | -$8.22M* | (m) | $7.72M | $1.78M | (m) |
| 2013-06-30 | Reported | (m) | -$6.89M | (m) | (m) | (m) | $699.00K* | -$8.11M* | (m) | $7.99M | $2.18M | (m) |
| 2013-03-31 | Reported | (m) | -$4.43M | (m) | (m) | (m) | $642.00K | -$9.59M | (m) | $7.75M | $2.10M | (m) |
| 2012-09-30 | Reported | (m) | -$5.56M | (m) | (m) | (m) | $770.00K* | -$8.03M* | (m) | $8.33M | (m) | (m) |
| 2012-06-30 | Reported | (m) | $9.62M | (m) | (m) | (m) | $237.00K* | $13.12M* | (m) | $10.54M | (m) | (m) |
| 2012-03-31 | Reported | (m) | -$6.07M | (m) | (m) | (m) | $810.00K | -$6.28M | (m) | $8.85M | (m) | (m) |
| 2011-09-30 | Reported | (m) | -$8.77M | (m) | (m) | (m) | $985.00K* | -$8.15M* | (m) | $9.34M | (m) | (m) |
| 2011-06-30 | Reported | (m) | -$13.87M | (m) | (m) | (m) | $1.41M* | -$4.82M* | (m) | $8.77M | (m) | (m) |
| 2011-03-31 | Reported | (m) | -$5.04M | (m) | (m) | (m) | $2.60M | -$3.99M | (m) | $10.56M | (m) | (m) |
| 2010-09-30 | Reported | (m) | -$2.85M | (m) | (m) | (m) | $1.34M* | -$9.68M* | (m) | $6.32M | (m) | (m) |
| 2010-06-30 | Reported | (m) | -$10.15M | (m) | (m) | (m) | (m) | (m) | (m) | $10.35M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$5.50M | (m) | (m) | (m) | $1.64M | -$11.99M | (m) | $19.57M | $11.68M | $996.00K |
| 2024-12-31 | Reported | (m) | $3.92M | (m) | (m) | (m) | $1.28M | $8.67M | (m) | $12.97M | $12.19M | $1.22M |
| 2023-12-31 | Reported | (m) | $10.46M | (m) | (m) | (m) | $1.15M | -$1.32M | (m) | $17.09M | $14.96M | $254.00K |
| 2022-12-31 | Reported | (m) | -$13.01M | (m) | (m) | (m) | $628.00K | -$25.00M | (m) | $29.35M | $11.71M | $530.00K |
| 2021-12-31 | Reported | (m) | -$20.46M | (m) | (m) | (m) | $1.46M | -$10.29M | (m) | $29.73M | $12.73M | (m) |
| 2020-12-31 | Reported | (m) | $2.71M | (m) | (m) | (m) | $655.00K | -$26.11M | (m) | $38.17M | $11.15M | (m) |
| 2020-09-30 | Rolling | (m) | $2.07M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | Rolling | (m) | $3.11M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | Rolling | (m) | -$490.00K* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | Reported | (m) | -$10.72M | (m) | (m) | (m) | $627.00K | -$19.36M | (m) | $44.62M | $9.90M | (m) |
| 2019-12-31 | Rolling | (m) | -$10.72M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | Rolling | (m) | -$16.59M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | Rolling | (m) | -$18.79M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | Rolling | (m) | -$19.69M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | Reported | (m) | -$19.31M | (m) | (m) | (m) | $686.00K | -$7.74M | (m) | $33.33M | $10.92M | (m) |
| 2018-12-31 | Rolling | (m) | -$19.31M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | Reported | (m) | -$34.52M | (m) | (m) | (m) | $971.00K | -$9.99M | (m) | $32.17M | $11.53M | (m) |
| 2016-12-31 | Reported | (m) | -$33.16M | (m) | (m) | (m) | $849.00K | -$32.10M | (m) | $30.41M | $9.36M | (m) |
| 2015-12-31 | Reported | (m) | -$23.67M | (m) | (m) | (m) | $464.00K | -$24.28M | (m) | $24.89M | $7.28M | (m) |
| 2014-12-31 | Reported | (m) | -$28.56M | (m) | (m) | (m) | $785.00K | -$29.28M | (m) | $27.35M | $9.23M | (m) |
| 2013-12-31 | Reported | (m) | -$34.06M | (m) | (m) | (m) | $1.89M | -$30.65M | (m) | $29.23M | $8.05M | (m) |
| 2012-12-31 | Reported | (m) | -$12.17M | (m) | (m) | (m) | $2.07M | $635.00K | (m) | $36.66M | $9.76M | (m) |
| 2011-12-31 | Reported | (m) | -$36.53M | (m) | (m) | (m) | $5.71M | -$23.57M | (m) | $37.82M | (m) | (m) |
| 2010-12-31 | Reported | (m) | -$29.97M | (m) | (m) | (m) | $7.86M | -$38.46M | (m) | $37.69M | (m) | (m) |
| 2009-12-31 | Reported | (m) | -$31.97M | (m) | (m) | (m) | $6.20M | $44.45M | (m) | $27.39M | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |